RT Journal Article
T1 COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort
A1 Calle Rubio, Myrian
A1 Rodríguez Hermosa, Juan Luis
A1 Torres, Juan P. de
A1 Marín, José María
A1 Martínez-González, Cristina
A1 Fuster, Antonia
A1 Cosío, Borja G.
A1 Peces-Barba, Germán
A1 Solanes, Ingrid, Jose Luis
A1 Feu-Collado, Nuria
A1 Lopez-Campos, José Luis
A1 Casanova, Ciro
AB 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 (52.1%) changed control status during follow-up. The variables significantly associated with persistent control were not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All-cause mortality was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all-cause mortality was 2.274 (95% CI 1.394–3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow-up period, 20% had scaled up their treatment, with triple therapy being the most frequent therapeutic pattern.
PB BMC
SN 1465-993X
YR 2021
FD 2021-02-04
LK https://hdl.handle.net/20.500.14352/98348
UL https://hdl.handle.net/20.500.14352/98348
LA eng
NO Calle Rubio M, Rodriguez Hermosa JL, de Torres JP, Marín JM, Martínez-González C, Fuster A, Cosío BG, Peces-Barba G, Solanes I, Feu-Collado N, Lopez-Campos JL, Casanova C; CHAIN Study Investigators. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. Respir Res. 2021 Feb 4;22(1):36.
DS Docta Complutense
RD 5 abr 2025